Section of Hematology / Oncology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|MD||2003||The University of Chicago, Pritzker School of Medicine||
|Residency||2006||New York University Medical Center||
|Fellowship||2009||University of Chicago||Hematology/Oncology
Dr. Szmulewitz is a physician scientist whose primary academic focus is on characterizing and controlling the process of metastatic progression in men with prostate cancer. He has a laboratory working with proteins called “metastasis suppressors” to slow down the growth of disseminated tumors in models of metastatic prostate cancer. In addition, Dr. Szmulewitz’s translational laboratory is using novel techniques to isolate and characterize prostate cancer cells from the blood of men with advanced prostate cancer. It is his goal to use these techniques to better personalize targeted therapies for metastatic prostate cancer.
High risk/locally advanced and metastatic prostate cancer;therapeutic development in prostate cancer, including immunotherapy ;bladder, testicular, renal cancer
- Szmulewitz RZ, Mohile S, Posadas EM, Kunnavakkam R, Karrison T, Stadler WM. “A Randomized Phase I Study of Testosterone Replacement for Patients with Low Risk Castrate Resistant Prostate Cancer.” European Urology. 2009. [e-pub 2/27/09]
- Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Vander Griend D, Yamada SD, Macleod K, Rinker-Schaeffer CW. “New Paradigms for the Function of JNKK1/MKK4 in Controlling Growth of Disseminated Cancer Cells”. Cancer Letters. 2008, June 20.
- Szmulewitz RZ, Posadas EM. “Antiandrogen therapy for prostate cancer.” Update on Cancer Therapeutics. 2007; 2: 119-131.
- Stadler WM, Szmulewitz RZ. “ Sunitinib-a new standard of care for metastatic renal cell cancer.” Nature Clinical Practice Oncology. 2007 Aug; 4(8): 458-459.
- Jayram, G, Szmulewitz RZ, Eggener S. “Management of good-risk nonseminomatous germ cell tumors of the testes: current concepts and controversies.” Indian Journal of Urology. 2010, Jan-Mar; 26(1): 68-73.